Apotex Targets Exclusivity Period In Generic Benicar Suit

Law360, New York (November 20, 2012, 7:43 PM EST) -- Apotex Inc. slapped Daiichi Sankyo Co. Ltd. with a patent suit in Illinois on Tuesday, seeking a noninfringement ruling which Apotex said could strip Mylan Laboratories Ltd. of exclusive rights to market a generic version of the hypertension drug Benicar.  

Matrix Laboratories Ltd., now Mylan Laboratories Ltd., was the first generic applicant to file a paragraph IV certification challenging U.S. Patent Numbers 5,616,599 and 6,878,703 with respect to 5-, 20- and 40-milligram olmesartan medoxomil — generic Benicar — tablets, the complaint said.

Daiichi sued Matrix but...
To view the full article, register now.